ENDRA Life Sciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the certified results of the 2019 Annual Meeting of Stockholders held by ENDRA Life Sciences Inc. on May 16, 2019. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Proposal 1 (Election of Directors): Stockholders elected five directors nominated by the Board. All nominees received significant support, though a substantial number of broker non-votes were recorded.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes cast for each director to assess shareholder engagement.
- Review the full Proxy Statement filed on April 15, 2019, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.